As the epidemic continues to spread rapidly around the world, COVID-19 vaccine has become the best-selling vaccine product in the history of the world, resulting in a significant increase in the performance of vaccine manufacturers.

According to Sino Biopharmaceutical's semi-annual report disclosed on August 31st, the profit attributable to the owner of the parent company was about 8.48 billion yuan, an increase of 583.6% over the same period last year, of which the profit contributed by the associated company and the joint venture company was 7.585 billion yuan, mainly from the 15.03% equity income held by Sinovel.. According to this estimate, Sinovel made a profit of nearly 50 billion yuan in the first half of the year, exceeding market expectations of 3-40 billion yuan.

According to Guotai Junan's previous calculation, the net profit of each inactivated vaccine is about 50 yuan, and the net interest rate is about 40% 50%. It is estimated that the sales income of Kexing vaccine in the first half of the year is 100 billion-125 billion yuan.

According to Sino Biopharmaceutical, Sinopec has completed more than 1 billion doses of vaccination worldwide, and Sinovel has signed cooperation agreements with nearly 20 countries outside China this year totaling about 900 million doses.

Global vaccine manufacturers are selling well.

As of April 3, five novel coronavirus vaccines have been approved for use in China, according to data released by the National Health Commission. It can be divided into three categories according to the technical route:

One is inactivated vaccine, including three kinds of inactivated vaccine produced by Zhongsheng Beijing Company, Zhongsheng Wuhan Company and Beijing Kexing Zhongwei Company; the second is adenovirus vector vaccine, which is produced by Tianjin CANSINOBIO Company; and the third is recombinant protein vaccine, which is recombinant novel coronavirus vaccine (CHO cell).

There is no doubt that COVID-19 vaccine is the best-selling vaccine product in the history of the world.

At present, in addition to Hexing vaccine, the sales revenue of other domestic vaccines is also very considerable, even exceeding the sales income of COVID-19 vaccine of many international pharmaceutical giants.

CANSINOBIO Co., Ltd. (CANSINOBIO, 688185.SHJING 06185.HK), the 2021 semi-annual report data released on the evening of August 27th showed that the income in the first half of the year was about 2.06 billion yuan (domestic / overseas accounted for 48% of 52% respectively), and the net profit was 937.1 million yuan, compared with a loss of 102 million yuan in the same period last year.

Concino adenovirus vector COVID-19 vaccine was approved to be listed conditionally in China on February 25th and supplied to Mexico, Pakistan and other countries, with an annual design capacity of 500-600 million doses.

Chongqing Zhifei Biological products Co., Ltd. (Zhifei Biology, 300122), the data of the 2021 semi-annual report released on the evening of August 29th showed that the revenue in the first half of the year was 13.171 billion yuan, and the net profit belonging to the shareholders of the listed company was 5.491 billion yuan. The semi-annual report shows that during the reporting period, the company has a total of 10 products on the market and one product for emergency use.

The COVID-19 vaccine of Zhifei recombinant protein was approved for emergency use in China on March 10. the income of 21H1 is about 5.3 billion yuan. It is estimated that the shipment of H1 is more than 100 million doses, the annual production capacity of the original liquid can reach 1 billion doses, and the annual production capacity of the preparation can reach 600 million doses.

Shanghai Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Shanghai Fosun Pharmaceutical, 600196.SHPower02196.HK) released its 2021 semi-annual report on the evening of Aug. 23, with operating income of 16.952 billion yuan in the first half, up 20.85% over the same period last year. Net profit belonging to shareholders of listed companies was 2.482 billion yuan, up 44.77% from the same period last year. Net profit belonging to shareholders of listed companies was 1.57 billion yuan after deducting non-recurring profits and losses, up 20.38% from the same period last year.

In the financial report, Shanghai Fosun Pharmaceutical directly disclosed COVID-19 vaccine-related sales data. The mRNA COVID-19 vaccine Fubitai, which he cooperated with Germany, was included in the government vaccination program in Hong Kong and Macao in China in the first half of the year, with an income of more than 500 million yuan during the reporting period.

Kangtai new crown inactivated vaccine was approved for emergency use in China on May 14. The income of 21H1 is about 160 million yuan. H1 is expected to ship about 4 million doses, and the annual production capacity is expected to exceed 200 million doses.

In addition to the above COVID-19 vaccine sales data, China Biological, the national pharmaceutical group that owns the two inactivated vaccines, is not a listed company, so it does not have public data. In addition, although some listed companies have participated in the research and development of the new crown vaccine, COVID-19 vaccine sales data have not yet been reflected in the semi-annual report.

With the smooth climbing of production capacity and the opening of overseas export markets, it is expected to continue to contribute to performance flexibility.

At the same time, Guotai Junan believes that "overseas COVID-19 vaccine performance is also excellent, and global COVID-19 vaccine sales are expected to exceed 100 billion US dollars in 2021." "

It wrote in the report:

Pfizer Inc: the mRNA COVID-19 vaccine BNT162b2 jointly developed by Pfizer Inc and BioNTech had a sales revenue of nearly US $7.9 billion in the second quarter, bringing a total of more than US $11.3 billion to Pfizer Inc in the first half of the year. As of July 28, the cumulative shipment of more than 1 billion doses is expected to supply 2.1 billion doses for the whole year, with an estimated revenue of 33.5 billion US dollars.

BioNTech, as a partner of Pfizer Inc, its 21H1 COVID-19 earns 7.3 billion euros, mainly from Pfizer Inc's gross profit share, and is expected to achieve 15.9 billion euros in revenue for the whole year.

The global "King of Medicine" Sumero has annual sales of US $20 billion. According to the above vaccine data, the annual sales of Pfizer Inc / BioNTech COVID-19 vaccine are expected to surpass Xiumile to become the new "medicine king".

Moderna21H1 COVID-19 shipped 300 million doses, with revenue of about US $5.93 billion, and is expected to supply 800-10 billion doses for the whole year, with an estimated revenue of US $20 billion.

AstraZeneca PLC 21H1 COVID-19 shipped 319 million doses with revenue of about US $1.17 billion.

Johnson & Johnson 21H1 COVID-19 earns $264 million and is expected to achieve an income of $2.5 billion for the whole year.

Combined with the current production capacity and orders of enterprises at home and abroad, it is predicted that the global sales of COVID-19 vaccine are expected to exceed 100 billion US dollars in 2021.